False-positive SARS-CoV-2 serology in 3 children with Kawasaki disease

Kelvin KW To a,1, Gilbert T. Chua b,1, Ka Li Kwok c, Joshua SC Wong d, Dennis Chi Yu Au d, Yuen Yu Lam c, Wilfred HS Wong b, Marco HK Ho b, Godfrey CF Chan b, Celine SL Chui b,c, Xue Li b,c, Keith TS Tung b, Rosa S Wong b, Winnie WY Tso b, Ian CK Wong f, Christina SM Wong g, Carol HY Fong a, Kwok Hung Chan a, Kwok Yung Yuen a,* Patrick Ip b,** Mike YW Kwan d,***

a Department of Microbiology, Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China
b Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China
c Department of Paediatrics, Kwong Wah Hospital, Hong Kong, SAR, China
d Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong, SAR, China
e Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong, SAR, China
f Research Department of Practice and Policy, UCL School of Pharmacy, University College, London, United Kingdom
g Department of Medicine, Queen Mary Hospital, Hong Kong, SAR, China

A R T I C L E   I N F O
Article history:
Received 15 June 2020
Received in revised form 6 July 2020
Accepted 9 July 2020
Available online xxx

Keywords:
Kawasaki disease
COVID-19
False positive
Serology
Chinese

A B S T R A C T
Background: Kawasaki disease (KD) is an acute febrile and eruptive disease with systemic vasculitis predominantly affecting young East Asian children. Recent reports showed that children with KD-like disease from KD low prevalence regions had positive SARS-CoV-2 serology despite a negative SARS-CoV-2 polymerase chain reaction (PCR) in respiratory samples.
Objectives: To describe 3 pediatric Kawasaki Disease patients with false positive SARS-CoV-2 serology.
Study design: We retrospectively recruited children with KD diagnosed during the COVID-19 outbreak in Hong Kong. Clinical characteristics and laboratory test results including SARS-CoV-2 PCR results were retrieved. We performed a microparticle-based immunoassay for the detection of IgG against nucleoprotein (NP) and spike protein receptor binding domain (RBD), and a microneutralization assay for the detection of neutralizing antibodies.
Results: Three Chinese children with typical KD were identified. They had no epidemiological links with COVID-19 patients and tested negative for SARS-CoV-2 NPA PCR. They were treated with IVIG and aspirin, and were discharged without complications. Subsequently 2 of them were tested positive against anti-RBD and anti-NP antibodies and 1 was tested positive against anti-RBD antibodies. However, microneutralization assay showed that neutralizing antibodies were absent, suggesting a false-positive IgG result.
Conclusion: Detection of neutralizing antibodies is recommended to confirm previous SARS-CoV-2 infection in IgG-positive but PCR-negative patients.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Background

Kawasaki disease (KD) is an acute systemic vasculitis complicated by coronary aneurysms that predominantly occurs in young East Asian children. Typical symptoms include fever for more than 5 days, exanthema, lymphadenopathy, conjunctival injection, altered oropharyngeal mucosa, and extremity changes. The etiology of KD remains uncertain and cases remain rare (McCrindle et al., 2017). Nevertheless, an upsurge of KD cases in Europe was observed during the Coronavirus Disease 2019 (COVID-19) pandemic. Out of the 10 KD cases reported in children from Bergamo, Italy, 2 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR, whereas 8 tested positive for SARS-CoV-2 antibodies (Viner and Whittaker, n.d.). A similar cluster of KD cases in children was reported in France during the outbreak, in which 14 children tested positive for SARS-CoV-2 IgG, but only 7 children tested positive for SARS-CoV-2 by PCR. As KD is known to be more prevalent in Hong Kong than in Europe (Uehara and Belay, 2012; Ng et al., 2005) and Hong Kong was close to the epicenter of the initial COVID-19 outbreak, concerns have been raised about new cases of KD in Hong Kong children during the outbreak and whether they were associated with SARS-CoV-2 infection. Therefore,
serological testing for SARS-CoV-2 was offered to Hong Kong children diagnosed with KD between January and April 2020.

2. Objective

We aim to describe 3 pediatric Kawasaki Disease patients diagnosed during the COVID-19 outbreak with false positive SARS-CoV-2 serology.

3. Methods

Children diagnosed with KD between January and April 2020 were identified. Their clinical and laboratory data were reviewed. Serological testing was performed to determine possible exposures to SARS-CoV-2. This study was approved by the University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (Reference number: UW 20–292). Written consent was obtained from parents prior to testing.

3.1. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays for SARS-CoV-2 RNA testing of respiratory specimens

Nasopharyngeal swabs (NPS) obtained during admission were tested by RT-PCR using the LightMix® Modular SARS and Wuhan CoV E-gene kit (TIB Molbiol, Berlin, Germany) on a LightCycler Multiplex RNA Virus Master (Roche, Penzberg, Germany) according to the manufacturer's instructions.

3.2. Detection of IgG against SARS-CoV-2 nucleoprotein and spike protein receptor binding domain

Blood (5 mL) was collected from each patient and serum was obtained for the detection of IgG against SARS-CoV-2 nucleoprotein (NP) and spike protein receptor binding domain (RBD) using a microsphere-based antibody assay as described previously (Fong et al., 2020). IgM was not measured in this assay. Briefly, cloning and purification of SARS-CoV-2 NP and spike RBD were performed as described previously (To et al., 2020). Both proteins were biotinylated using EZ-link™ Sulfo-NHS-Biotin (ThermoFisher Scientific, MA, USA). SuperAvidin™ coated microspheres (Bangs Laboratories, Indiana, USA) were coated with biotinylated NP or spike RBD and then mixed with serum at a dilution of 1:400. Bound antibodies were detected with Alexa Fluor® 647 AffinPure Fab fragment goat anti-human IgG. Flow cytometry was performed on a BD LSR Fortessa analyzer (BD Biosciences, San Jose, CA, USA) and data were analyzed using FlowJo v10.6.2 (FlowJo LLC, Ashland, OR, USA).

3.3. Microneutralization (MN) assay

Virus culture and MN assay were performed as previously described (To et al., n.d., 2020b). Briefly, serum samples (50 μL) were prepared in minimum essential medium and mixed with SARS-CoV-2 (50 μL) to give a serum dilution of 1:10 and a final virus inoculum of 100 TCID50. The serum-virus mixture was incubated at 37 °C for 1 hour and then added to VeroE6 cells and incubated at 37 °C and 5% CO2 for 72 hours. Cytopathic effects were determined under inversion microscopy. The MN antibody titer was determined as the highest dilution showing 50% inhibition of CPE. An MN titer ≥10 was considered positive as described previously (Okba et al., 2020).

4. Results

Three Chinese children, who had no epidemiological links with COVID-19 patients were diagnosed with typical KD during the peak of COVID-19 outbreak in Hong Kong (Table 1). They were tested negative for SARS-CoV-2 and other common respiratory pathogens in nasopharyngeal aspirate polymerase chain reaction (PCR), including respiratory syncitial virus, adenovirus, human metapneumovirus, influenza A and B, parainfluenza virus type 1, 2, 3, 4, rhinovirus, bocavirus, enterovirus, coronavirus 229E, NL63, HKU1, and OC43, Bordetella pertussis, Bordetella parapertussis, Chlamydia pneumoniae and Mycoplasma pneumoniae. They achieved complete recovery with one dose of intravenous immunoglobulins at 2g/kg, high-dose aspirin at 30–50 mg/kg per day until 2 days after defervescence, followed by low-dose aspirin at 3–5 mg/kg per day for 8 weeks. In view of the possible association between KD and COVID-19 infection, they were called back to test for SARS-CoV-2 anti-NP and anti-RBD antibodies 60–90 days after the diagnosis of KD. Patient 1 tested positive for SARS-CoV-2 anti-RBD IgG, whereas both patients 2 and 3 tested positive for SARS-CoV-2 anti-NP and anti-RBD IgG. However, all 3 patients tested negative with the microneutralization assay, suggesting that the IgG results were false positives.

5. Discussion

To the best of our knowledge, this is the first report demonstrating false-positive SARS-CoV-2 serology among KD children. The 3 patients reported in this study did not report any epidemiological links to individuals with COVID-19 or any travel history in areas with COVID-19 outbreaks. They did not report any symptoms or signs of SARS-CoV-2 prior to admission for KD. Only SARS-CoV-2 anti-RBD IgG was detected in 1 patient, whereas both anti-NP and anti-RBD IgG were detected in 2 patients. However, no neutralizing antibodies were detected in any of the patients by MN assay, suggesting the antibodies detected in the serology assay were unlikely to be related to a prior SARS-CoV-2 infection. The serological assay used in this study has sensitivity of 89.8% for anti-NP IgG and 79.5% for anti-RBD IgG, as well as specificity of 100% for anti-NP IgG and 98.9% for anti-RBD IgG when evaluated using sera collected from influenza patients or organ donors before 2020 (Fong et al., 2020). The false-positive results from the serological testing could possibly be due to the presence of cross-reactive antibodies elicited by other triggers, such as non-specific antibodies triggered by Kawasaki Disease reacting to NP, RBD or any reagents in the blocking buffer; or cross-reactive antibodies triggered by other coronaviruses. False-positive results have been well reported in serological testing for immune responses against viral infections, such as false positives in hepatitis A and cytomegalovirus serologies from Epstein-Barr virus infection (Miedjde et al., 2000; Valota et al., 2019). We believe the false positive SARS-CoV-2 serology results were unrelated to the administration of IVIG for treating KD. First, the time interval between IVIG administration and serology testing ranged between 60 and 90 days, whereas the median half-life of IVIG is 21 days (Koleba and Ensom, 2006). Second, the IVIG treatment, Intragram® P (CSL Behring Asia Pacific Limited), was manufactured from the pooled plasma of healthy Hong Kong blood donors and had been made months before its use (Barahona Afonso and João, 2016), and therefore unlikely to contain any plasma from donors with COVID-19, as the first case of COVID-19 was diagnosed in Hong Kong in late January 2020 (Leung et al., 2020).

The association between KD and COVID-19 remains unclear. To date, a total of 4 case series and reports on 40 patients have proposed a possible link between COVID-19 and KD (Jones et al., 2020; Verdoni et al., n.d.; Toubiana et al., 2020; Riphagen et al., 2020). Although 11 patients were confirmed to have COVID-19 by a positive SARS-CoV-2 PCR in respiratory specimens, the other patients were reported to have positive SARS-CoV-2 serology without confirmation by microneutralization assay (Table 2). Thus, the possibility that these patients might have false positive results cannot be ruled out. Clinically, not all the patients in these case series presented with KD symptoms reported in cases in Asia, which typically involved younger children under 4 years and...
| No. | Age/ Gender  | Significant Past Health | COVID-19 Contact | Symptoms                                                                 | Respiratory Virus PCR⁴ | SARS-CoV-2 PCR⁵ | Echo                                         | Serology (Number of Days taken after IVIG) | MN | Treatment | Outcome                           |
|-----|--------------|-------------------------|------------------|---------------------------------------------------------------------------|------------------------|-----------------|---------------------------------------------|---------------------------------------------|----|-----------|------------------------------------|
| 1   | 3 months/F   | None                    | None             | Rhinorrhea • Blocked Nose • 7 days of fever • Conjunctivitis • Cracked lips • MP rash • Cough and Rhinorrhea • Conjunctivitis • Cervical lymphadenopathy • MP rash • Erythematous Lips • Swelling of hands and feet • Erythema of BCG scar | Negative              | Negative        | Perivascular echogenicity and non-tapering coronary arteries | Anti-RBD IgG positive (90 days)                | Negative  | IVIG       | 2 g/kg Aspirin⁶ Resolution of fever and KD features. Normal coronary arteries at 12-week follow-up. |
| 2   | 6 months/F   | None                    | None             | EV/RV • Cough • Rhinorrhea • 6 days of fever • Conjunctivitis • MP rash • Erythematosus lips • 5 days of fever • Cough and Rhinorrhea • Conjunctivitis • Cervical lymphadenopathy • MP rash • Erythematous Lips • Swelling of hands and feet • Erythema of BCG scar | Negative              | Negative        | Perivascular echogenicity and non-tapering coronary arteries | Anti-RBD and anti-NP IgG positive (87 days) | Negative  | IVIG       | 2 g/kg Aspirin⁶ Resolution of fever and KD features. Normal coronary arteries at 8-week follow-up. |
| 3   | 3 months/M   | None                    | None             | Negative                  | Negative              | Normal          |                                  | Anti-RBD and anti-NP IgG positive (60 days) | Negative  | IVIG       | 2 g/kg Aspirin⁶ Resolution of fever and KD features. Normal coronary arteries at 2-week follow-up. |

Echo = echocardiogram, EV/RV = enterovirus/rhinovirus, IVIG = intravenous immunoglobulin, MN = microneutralization assay, MP = maculopapular, NP = nucleoprotein, RBD = receptor binding domain.

* Initial high-dose aspirin at 30–50 mg/kg per day until 2 days after defervescence, followed by low-dose aspirin at 3–5 mg/kg per day for 8 weeks.
* Nasopharyngeal swab specimen.
* Pooled nasopharyngeal and throat swab specimens.
commonly included symptoms such as erythema and swelling of BCG scars (Nagata, 2019). Epidemiologically, there was a 30-fold increase in the monthly incidence of KD in Italy during the COVID-19 pandemic, whereas the incidence of KD in Hong Kong remained the same (unpublished data). Furthermore, we reviewed all NPS samples from KD patients admitted to public hospitals in Hong Kong, which were all negative for SARS-CoV-2 PCR. Data from Wuhan Children’s Hospital in China reported 244 children with COVID-19, but none showed any symptoms and signs of KD (submitted and under review). Large-scale observational studies are needed to determine whether the reported cases belong to classical KD or another form of hyperinflammatory disease, recently termed pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Frontline clinicians should be aware of the potential false-positive IgG results. Patients with positive SARS-CoV-2 serology but negative PCR should be further tested by MN assay for the presence of neutralizing antibodies.

Acknowledgement

Declaration of interest

None

Funding source

Richard Yu and Carol Yu, May Tam Mak Mei Yin, Michael Seak-Kan Tong, the Respiratory Viral Research Foundation, Hui Ming, Hui Hoy and the Chow Sin Lan Charity Fund, Chan Yin Chuen Memorial Charitable Foundation, Marina Man-Wai Lee, the Jessie & George Ho Charitable Foundation, Perfect Shape Medical, and Kai Chong Tong.

References

Barahona Afonso AF, João CMP. The Production Processes and Biological Effects of Intravenous Immunoglobulin. Biomolecules 2016;6(1):15. https://doi.org/10.3390/biom6010015.
Fong CHY, Dissanayake TK, Chen L-L, et al. Improved detection of antibody against SARS-CoV-2 by microsphere-based antibody assay. medRxiv 2020. 2020.05.26.20113191. https://doi.org/10.1101/2020.05.26.20113191.
Jones V C, Mill M, Suarez D, et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. Hosp Pediatr 2020. https://doi.org/10.1542/hpeds.2020-0123. [published Online First: 2020/04/09].
Koleba T, Ensom MH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy 2006;26(6):813–27. https://doi.org/10.1592/phco.2006.26.6.813. [published Online First: 2006/05/24].
Leung GM, Cowling BJ, Wu JT. From a Sprint to a Marathon in Hong Kong. N Engl J Med 2020, e45. https://doi.org/10.1056/NEJMc2009790.
McCrudden BW, Rowley AH, Newburger JW, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation 2017;135(17):e927–99. https://doi.org/10.1161/CIR.0000000000000484. [published Online First: 2017/07/31].
Miedje Deyi Y, Goubau P, Bodéus M. False-positive IgM antibody tests for cytomegalovirus in patients with acute Epstein-Barr virus infection. Eur J Clin Microbiol Infect Dis 2000;19(7):557–60. https://doi.org/10.1007/s100960000317. [published Online First: 2000/05/01].
Nagata S. Causes of Kawasaki Disease—From Past to Present. Front Pediatr 2019;7:18. https://doi.org/10.3389/fped.2019.00018.
Ng YML, Sung WY, So B, et al. Kawasaki disease in Hong Kong, 1994 to 2000. Hong Kong Med J 2005;11(5):331–5. [published Online First: 2005/10/13].
Okba NM, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. medRxiv 2020. https://doi.org/10.1101/2020.03.18.20038099.
Rijpma S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020;395(10237):1607–8. https://doi.org/10.1016/S0140-6736(20)31094-9.
To KK Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020a. 39(5):1607–8. https://doi.org/10.1016/S1473-3099(20)30196-1.
To KK Tsang OT, VC C, et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020b. https://doi.org/10.1093/cid/ciaa419.
To KK-W, Cheng VC-C, Chan JFY, et al. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe doi: https://doi.org/10.1016/S2586-5247(20)30053-7.
Toubiana J, Poirault C, Corsia A, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ 2020;369, m2094. https://doi.org/10.1136/bmj.m2094.

Uehara R, Belay ED. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012;22(2):79–85. https://doi.org/10.2188/jea.je20110131. published Online First: 2012/02/04.

Valota M, Thienemann F, Misselwitz B. False-positive serologies for acute hepatitis A and autoimmune hepatitis in a patient with acute Epstein-Barr virus infection. BMJ Case Rep 2019;12(5). https://doi.org/10.1136/bcr-2018-228356. published Online First: 2019/05/13.

Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet doi: https://doi.org/10.1016/S0140-6736(20)31103-X.

Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet doi: https://doi.org/10.1016/S0140-6736(20)31129-6.